A GCLC Inhibitor Enhances the Antitumor Efficacy of Glutathione Metabolic Pathway Inhibition in SMARCB1-Deficient Rhabdoid Tumors - PubMed
4 hours ago
- #ferroptosis
- #GCLC inhibitor
- #SMARCB1-deficient cancers
- GCLC inhibitors (GCLCi0 and GCLCi1) show potent anti-tumor effects in SMARCB1-deficient cancers.
- Inhibition of GCLC depletes glutathione (GSH), increases ROS, and induces ferroptotic cell death.
- SMARCB1-deficient cells have low SLC7A11 expression, making them sensitive to GCLC inhibition.
- Combining GCLC inhibitors with SLC7A11 inhibitors or telaglenastat enhances anti-tumor efficacy.
- The study supports GCLC inhibitors as a promising therapeutic strategy for SMARCB1-deficient cancers.